Related Experiment Video
Updated: Sep 20, 2025
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
Xueyin Zhou1, Ting Ren2, Hongyuan Zan1
1School of Medicine, Wenzhou Medical University, Wenzhou, China.
Abstract:
Esophageal cancer ranks as the sixth most common cause of cancer death worldwide. Due to the limited efficacy of conventional therapeutic strategies, including surgery, chemotherapy, and radiotherapy, treatments are still far from satisfactory in terms of survival, prompting the search for novel treatment methods. Immune checkpoints play crucial roles in immune evasion mediated by tumor cells, and successful clinical outcomes have been achieved via blocking these pathways. However, only a small fraction of patients can benefit from current immune checkpoint inhibitors targeting programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated protein-4. Unfortunately, some patients show primary and/or acquired resistance to immune checkpoint inhibitors. Until now, novel immune checkpoint pathways have rarely been studied in esophageal cancer, and there is a great need for biomarkers to predict who will benefit from existing strategies. Herein, we primarily discuss the roles of new immune checkpoints as predictive biomarkers and therapeutic targets for esophageal cancer. In addition, we summarize the ongoing clinical trials and provide future research directions targeting these pathways.
Insights
New immune checkpoints offer promising therapeutic targets and predictive biomarkers for esophageal cancer, addressing limitations of current treatments and resistance to immune checkpoint inhibitors.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Esophageal cancer is a leading cause of cancer death globally, with current treatments like surgery, chemotherapy, and radiotherapy showing limited efficacy.
- Immune checkpoint inhibitors targeting PD-L1 and CTLA-4 have shown success but benefit only a subset of patients, with many developing resistance.
- Novel immune checkpoint pathways in esophageal cancer remain understudied, highlighting a need for new biomarkers and therapeutic strategies.
Purpose of the Study:
- To explore the roles of novel immune checkpoints in esophageal cancer.
- To identify new predictive biomarkers for response to immunotherapy.
- To discuss potential therapeutic targets for improving esophageal cancer treatment.
Main Methods:
- Review of current literature on immune checkpoints in cancer.
- Analysis of the role of novel immune checkpoints in esophageal cancer immune evasion.
- Summary of ongoing clinical trials targeting new immune checkpoints.
Main Results:
- Novel immune checkpoints represent potential predictive biomarkers for esophageal cancer immunotherapy.
- Targeting these new pathways may overcome resistance to existing immune checkpoint inhibitors.
- Further research is needed to fully elucidate their therapeutic potential.
Conclusions:
- New immune checkpoints are critical for understanding and treating esophageal cancer.
- These pathways hold promise as both predictive biomarkers and therapeutic targets.
- Future research should focus on clinical validation and development of novel immunotherapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:38Mitogens and the Cell Cycle
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...